CASE REPORT

Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome

Shawg Ganawa1 | Smrithi Hema Santhosh1,2 | Lucy Parry1,3 | Akheel A. Syed1,4

1Diabetes, Endocrinology and Obesity Medicine, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK
2Undergraduate Medical Education, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK
3School of Medical Sciences, University of Manchester, Manchester, UK
4Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK

Correspondence
Akheel A. Syed, Department of Diabetes, Endocrinology and Obesity Medicine, Salford Royal NHS Foundation Trust, Salford M6 8HD, UK.
Email: akheel.syed@manchester.ac.uk

Summary
Bardet–Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.

KEYWORDS
Type 2 diabetes mellitus, glucagon-like peptide-1, hypothalamic diseases, incretins, Laurence-Moon–Bardet-Biedl syndrome, morbid obesity, weight loss

What is already known about this subject
- Bardet–Biedl syndrome (BBS) is a rare genetic condition associated with severe obesity from a young age.
- The options of weight management are limited, and efficacy of pharmacotherapy is unknown.

What this study adds
- We show significant weight reduction with lifestyle and dietary management alongside glucagon-like peptide-1 receptor agonist treatment in a young woman with BBS.
- Weight loss pharmacotherapy is a promising avenue of treatment in genetic obesity syndromes with several novel molecules on the horizon.

A 28-year-old woman was referred to our specialized complex obesity service with childhood-onset obesity associated with hyperphagia. She also had longstanding retinitis pigmentosa, acanthosis nigricans, polycystic ovarian syndrome, hypothyroidism and hypertension and recent-onset type 2 diabetes. Her body mass index (BMI) was 37.9 kg/m². There was no polydactyly. She was studying at university. She was taking metformin, ramipril and levothyroxine. A clinical diagnosis of Bardet–Biedl syndrome (BBS) was suspected, and genetic testing by Sanger sequencing confirmed homozygous c.1599_1602del p. (Thr53411efs*21) in the BBS10 gene (12q21.2).

Initial management was focused on weight reduction with lifestyle and dietary management. A dietary history established that there was a high intake of fizzy drinks, large portion sizes and mealtimes out of keeping with the norm. Changes included moving forward mealtimes, eating smaller portion sizes, eating foods with a low glycaemic index and removing fizzy drinks from the diet. She had
FIGURE 1 Clinical course of weight management in a patient with Bardet–Biedl syndrome. Weight (kg) depicted by blue trace, body mass index (BMI, kg/m²) by orange trace and glycated haemoglobin (HbA1c, mmol/mol) by yellow columns. Initial weight reduction with the sodium-glucose co-transporter-2 inhibitor, Canagliflozin, was short-lived and poorly tolerated. Treatment with glucagon-like peptide-1 receptor agonists (daily liraglutide initially, later replaced with weekly semaglutide, depicted by grey droplines) resulted in total weight loss of 33% and normalization of glycated haemoglobin. Lifestyle and dietary management and semaglutide therapy continue for long-term weight maintenance.

1 | DISCUSSION

Bardet–Biedl syndrome (BBS), a pleiotropic autosomal recessive disorder affecting ciliary protein function, is caused by biallelic loss-of-function pathogenic variants in one of at least 26 genes and is characterized by retinal dystrophy, obesity, post-axial polydactyly, renal dysfunction, learning difficulties and hypogonadism. Prevalence varies geographically with an estimated incidence of 1 in 160 000 new-borns in northern European populations. Obesity is a major clinical finding, affecting 72%–86% of people with BBS. While ciliary dysfunction may explain several features of BBS, the molecular aetiology of hyperphagia and resulting obesity remains to be fully elucidated. It has been associated with peripheral leptin resistance and abnormal adipogenesis. Type 2 diabetes is prevalent among patients, related to the severity of obesity, and is often found in association with other features of the metabolic syndrome, including hypertension and dyslipidaemia, which if left untreated may reduce life expectancy. In a case–control study comprising 152 patients with BBS who attended two specialist clinics in England compared to 103 individuals matched for age, sex and BMI, the prevalence of the metabolic syndrome in adults with BBS was 54% versus 26% in controls. Among patients with BBS, 76% had obesity, 16% had type 2 diabetes and 15% of the women had polycystic ovary syndrome. Of the 24 patients with BBS who had type 2 diabetes in this study, six patients were diet controlled, eight were taking metformin, and 10 used insulin to manage their diabetes with none reported to have been treated with GLP-1RAs.

The discovery of molecular mechanisms in obesity has progressed with advances in genetic screening, leading to recognition of different clinical presentations depending on the genes involved. Whereas polygenic (common) obesity results from multiple smaller gene mutations having a combined effect on the phenotype, monogenic obesity—a rare and severe form—occurs due to a single gene mutation substantial enough to cause disease. Examples of the latter include mutations in the genes encoding leptin, leptin receptor (LEPR) and melanocortin 4 receptor (MC4R). Pleiotropic obesity syndromes, such as Prader–Willi syndrome and BBS, are associated with mutations in several different genes.

While GLP-1RAs are widely used in the treatment of type 2 diabetes (all agents from this class) and more recently obesity (liraglutide and semaglutide), we are unaware of any reports of their use for weight reduction in BBS in the literature. Pharmacological activation of the widespread distribution of GLP-1 receptors within the CNS, including the hypothalamus, promotes satiety and controls appetite and body weight. Weight regain appears to be common upon cessation of treatment with semaglutide, and long-term weight loss maintenance is likely to require continuous use.

Several novel pharmacotherapies for obesity are on the horizon, including new GLP-1RAs, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, glucagon analogues, GLP-1/glucagon, GIP/GLP-1 and amylin/calcitonin dual agonists, and GIP/GLP1/glucagon tri-agonists. However, no specific pharmacological treatments exist for hyperphagia and obesity in most rare genetic obesity syndromes. Setmelanotide, an MC4R agonist acting in the brain to regulate food intake and satiety, approved for the treatment of obesity due to LEPR, pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiencies in adults and children, has been shown to reduce hunger and body weight in individuals with BBS. Further clinical trials are ongoing.

Bariatric surgery, the most effective therapy for severe obesity, is also effective in monogenic obesity due to MC4R deficiency, but is less well studied in pleiotropic obesity syndromes. In people with BBS, sleeve gastrectomy (n = 5), Roux-en-Y gastric bypass (n = 1), and adjustable gastric banding (n = 1) have been reported with...
limited, short-term outcome data. Future therapies for BBS could include gene replacement therapy, readthrough therapy, exon skipping therapy and genome editing.16

2 | CONCLUSION

We report significant weight reduction with GLP-1RA therapy in a young woman with BBS. Several novel therapeutic agents are on the horizon, but continuous use is likely to be necessary for weight loss maintenance. Futuristic gene therapies may be the holy grail of treatment for BBS and other genetic disorders of obesity.

ACKNOWLEDGEMENTS

We thank our patient for giving informed, signed consent to publication. We thank the Clinical Endocrinology Trust and the Society for Endocrinology for the award of best presentation in the Disorders of Appetite and Weight workshop at the SfE Clinical Update Meeting 2022, Birmingham, UK (25–27 April 2022); DOI: 10.1530/endoabs.82.WG1.

ORCID

Smrithi Hema Santhosh https://orcid.org/0000-0003-1060-3158
Akheel A. Syed https://orcid.org/0000-0001-8696-7121

REFERENCES

1. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011;364(16):1533-1543.
2. Forsyth RL, Gunay-Aygün M. Bardet-Biedl Syndrome Overview. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. University of Washington; 2003 (updated 2020).
3. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet. 2013;21(1):8-13.
4. Mujahid S, Hunt KF, Cheah YS, et al. The endocrine and metabolic characteristics of a large Bardet-Biedl syndrome clinic population. J Clin Endocrinol Metab. 2018;103(5):1834-1841.
5. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120-133.
6. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly Semaglutide in adults with overweight or obesity. New Eng J Med. 2021;384(11):989-1002.
8. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
9. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.
10. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223.
11. Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240-246.
12. Clément K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551-555.
13. Haws R, Brady S, Davis E, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133-2140.
14. Elkhenini HF, New JP, Syed AA. Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation. Clin Obes. 2014;4(2):121-124.
15. Gantz MG, Driscoll DJ, Miller JL, et al. Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders. Obesity (Silver Spring). 2022;30(5):973-981.
16. Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet-Biedl syndrome—now and in the future. Front Pediatr. 2018;6:23.

How to cite this article: Ganawa S, Santhosh SH, Parry L, Syed AA. Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome. Clinical Obesity. 2022;12(5):e12546. doi:10.1111/cob.12546